APLS — Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. (APLS) 是一家生物科技公司，屬於醫療保健產業, 目前交易價格為 $40.85. 其SharesGrow評分為 48/100, 表明一般的投資特徵， 7項中通過1項.

SharesGrow calculates the intrinsic value of APLS = $37.40 (-8.4% 相對於當前價格, 該股票看起來估值合理). 分析師共識目標價為 APLS = $34 (-18% 上漲空間).

估值: APLS 本益比(P/E)為 229.3 (S&P 500平均約25).

財務數據: 營收為 $1.0B, +183.8%/yr 平均成長. 淨利潤為 $22M, 成長率為 +64.3%/yr. 淨利潤率為 2.2% (較薄). 毛利率為 89.8% (-2.7 pp 趨勢).

資產負債表: 總債務為 $486M 對比 $370M 股東權益 (D/E比率 1.31, 適度). 流動比率為 3.14 (流動性強). 資產負債率為 45.2%. 總資產: $1.1B.

分析師展望: 18 / 25 位分析師評級 APLS 為買入 (72%) — 強烈共識.

SharesGrow 7項標準細分: Value 18/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 65/100 (Partial), Future 49/100 (Partial), Income 30/100 (Fail).

$33.50

▼ 17.99% 下跌空間

Average Price Target

基於 25 位華爾街分析師對 Apellis Pharmaceuticals, Inc. 提供的12個月價格目標，平均目標價為 $33.50，最高預測為 $52.00，最低預測為 $19.00。

Highest Price Target

$52.00

Average Price Target

$33.50

Lowest Price Target

$19.00

APLS SharesGrow 評分概覽

48/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

價值 18/100

估值 — P/E, PEG, Forward PEG

成長 100/100

財務數據 — 平均成長

過去 25/100

強勁 — 趨勢

健康 50/100

資產負債表 — D/E比率, 流動比率為

護城河 65/100

毛利率為 + market cap

未來 49/100

分析師展望 — 為買入

收入 30/100

淨利潤率為

Scores derived from financial statements, analyst ratings, and balance sheet data.

評分明細 — APLS

✗

價值 Fail

18/100

APLS 本益比(P/E)為 229.3 (S&P 500平均約25). Forward PEG -2.59 — Peter Lynch 被低估 (≤1.0). 分析師共識目標價為 $34, 意味著 -16.8% 相對於當前價格 $41. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + 上漲空間 (25%) + trailing PEG (20%). ≥ 60 = Pass.

APLS: +183.8%/yr 營收為, +64.3%/yr 淨利潤為平均成長. > 5%/yr — 強勁. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

APLS: 1 / 4 年獲利. 較弱. Score = 1 / 4 × 100. ≥ 80 = Pass.

資產負債表 APLS: D/E比率 1.31 (適度), 流動比率為 3.14 (流動性強). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

APLS: 毛利率為 89.8% (-2.7 pp 趨勢), $5B market cap. Moat (0-100): margin (35%) + 趨勢 (15%) + market cap (30%) + 營收為 (20%). Score 65/100. ≥ 70 = Pass.

分析師展望: 18 / 25 位分析師評級 APLS 為買入 (72%). 分析師共識目標價為 $34 (-16.8% 上漲空間). Score: 60% buy consensus + 40% 上漲空間. ≥ 60 = Pass.

APLS: 淨利潤率為 2.2%. 較薄 (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

市場數據

52週區間16.1-40.48

成交量3.99M

30日平均成交量5.05M

市值$5.22B

Beta（1年）-0.20

Share Statistics

EPS（TTM）0.18

流通股數$126.02M

IPO Date2017-11-09

Employees705

CEOCedric Francois

Financial Highlights & Ratios

Revenue (TTM)$1B

Gross Profit$901.55M

EBITDA$70M

Net Income$22.39M

Operating Income$55.43M

Total Cash$467.76M

Total Debt$486.31M

Net Debt$18.55M

Total Assets$1.08B

Price / Earnings (P/E)226.9

Price / Sales (P/S)5.2

Analyst Forecast

1Y Price Target$30.50

Target High$52.00

Target Low$19.00

上漲空間-25.3%

評級共識Buy

覆蓋分析師數25

買入 72% 持有 24% 賣出 4%

Price Target Summary

公司資訊

國家US

交易所NASDAQ Global Select

貨幣USD

ISINUS03753U1060

股價走勢

APLS

Apellis Pharmaceuticals, Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

16.10 52WK RANGE 40.48

其他人也在看

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

RXDX

Prometheus Biosciences, Inc.

$199.92

+0.09%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

CERE

Cerevel Therapeutics Holdings, Inc.

Terns Pharmaceuticals, Inc.

$52.68

+0.13%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

MRTX

Mirati Therapeutics, Inc.

$58.70

-0.17%

Apellis Pharmaceuticals, Inc. APLS NASDAQ

APLS SharesGrow 評分概覽

評分明細 — APLS

Stock Chart & Stats

股價走勢

其他人也在看

獲取低估股票提醒